TD 139

Drug Profile

TD 139

Alternative Names: TD-139

Latest Information Update: 21 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lund University; University of Edinburgh
  • Developer Galecto Biotech
  • Class Antifibrotics; Small molecules; Thioglycosides
  • Mechanism of Action Angiogenesis inhibitors; Galectin 3 inhibitors; Galectin-1-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis

Most Recent Events

  • 10 Mar 2017 Adverse events and pharmacokinetics data from a phase II trial in Idiopathic pulmonary fibrosis released by Galecto
  • 10 Mar 2017 Galecto plans a phase IIb trial for Idiopathic pulmonary fibrosis
  • 01 Dec 2016 Galecto Biotech completes a phase Ib/IIa trial in Idiopathic pulmonary fibrosis in United Kingdom (NCT02257177)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top